Literature DB >> 29467412

IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation.

Jaesuk Yun1,2, Mi Hee Park1, Dong Ju Son1, Kyung Tak Nam1, Dae Bong Moon1, Jung Heun Ju1, Ok Kyung Hwang1, Jeong Soon Choi1, Tae Hoon Kim1, Young Suk Jung1, Dae Yeon Hwang3, Sang Bae Han1, Do-Young Yoon4, Jin Tae Hong5.   

Abstract

The low expression of tissue inhibitor of metalloproteinase 3 (TIMP-3) is important in inflammatory responses. Therefore, inhibition of TIMP-3 may promote tumor development. Our study showed that expression of TIMP-3 was elevated in lL-32γ mice lung tissues. In this study, we investigated whether IL-32γ mice inhibited lung tumor development through overexpression of TIMP-3 and its methylation. To explore the possible underlying mechanism, lung cancer cells were transfected with IL-32γ cDNA plasmid. A marked increase in TIMP-3 expression was caused by promoter methylation. Mechanistic studies indicated that TIMP-3 overexpression reduced NF-κB activity, which led to cell growth inhibition in IL-32γ transfected lung cancer cells. We also showed that IL-32γ inhibits expression of DNA (cytosine-5-)-methyltransferase 1 (DNMT1). Moreover, IL-32γ inhibits the binding of DNMT1 to TIMP-3 promoter, but this effect was reversed by the treatment of DNA methyltransferase inhibitor (5-Aza-CdR) and NF-κB inhibitor (PS1145), suggesting that a marked increase in TIMP-3 expression was caused by inhibition of promoter hypermethylation via decreased DNMT1 expression through the NF-κB pathway. In an in vivo carcinogen induced lung tumor model, tumor growth was inhibited in IL-32γ overexpressed mice with elevated TIMP-3 expression and hypomethylation accompanied with reduced NF-κB activity. Moreover, in the lung cancer patient tissue, the expression of IL-32 and TIMP-3 was dramatically decreased at a grade-dependent manner compared to normal lung tissue. In summary, IL-32γ may increase TIMP-3 expression via hypomethylation through inactivation of NF-κB activity, and thereby reduce lung tumor growth.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467412      PMCID: PMC5833366          DOI: 10.1038/s41419-018-0375-6

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  49 in total

1.  Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells.

Authors:  Jie Hong; Dan Li; Jack Wands; Rhonda Souza; Weibiao Cao
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

2.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

Review 3.  IL-32, a novel cytokine with a possible role in disease.

Authors:  C A Dinarello; S-H Kim
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment.

Authors:  A J Staal-van den Brekel; M A Dentener; M Drent; G P ten Velde; W A Buurman; E F Wouters
Journal:  Respir Med       Date:  1998-01       Impact factor: 3.415

5.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Authors:  K E Bachman; J G Herman; P G Corn; A Merlo; J F Costello; W K Cavenee; S B Baylin; J R Graff
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 6.  Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32).

Authors:  P Conti; P Youinou; T C Theoharides
Journal:  Autoimmun Rev       Date:  2006-10-16       Impact factor: 9.754

7.  Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas.

Authors:  Ping Gu; Xiangbin Xing; Marc Tänzer; Christoph Röcken; Wilko Weichert; Audrius Ivanauskas; Matthias Pross; Ulrich Peitz; Peter Malfertheiner; Roland M Schmid; Matthias P A Ebert
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

8.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.

Authors:  L M Zheng; D M Ojcius; F Garaud; C Roth; E Maxwell; Z Li; H Rong; J Chen; X Y Wang; J J Catino; I King
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

9.  Polymorphisms in PRKCDBP, a Transcriptional Target of TNF-α, Are Associated With Inflammatory Bowel Disease in Korean.

Authors:  Jung-Wook Kim; Chang Kyun Lee; Hyo Jong Kim; Jae-Jun Shim; Jae Young Jang; Seok Ho Dong; Byung-Ho Kim; Young Woon Chang; Sung-Gil Chi
Journal:  Intest Res       Date:  2015-06-09

10.  The antitumor potential of Interleukin-27 in prostate cancer.

Authors:  Emma Di Carlo; Carlo Sorrentino; Alessia Zorzoli; Serena Di Meo; Maria Grazia Tupone; Emanuela Ognio; Gabriella Mincione; Irma Airoldi
Journal:  Oncotarget       Date:  2014-11-15
View more
  4 in total

Review 1.  Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties.

Authors:  Geetanjali P Rai; Sarah K Baird
Journal:  Clin Exp Metastasis       Date:  2020-01-01       Impact factor: 5.150

2.  IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway.

Authors:  Yong Sun Lee; Ki Cheon Kim; Raj Kumar Mongre; Ji Young Kim; Yu Ri Kim; Dong Young Choi; Sukgil Song; Jaesuk Yun; Sang-Bae Han; Do Young Yoon; Jin Tae Hong
Journal:  Cell Death Dis       Date:  2019-07-01       Impact factor: 8.469

3.  Identification of novel transcription factor-microRNA-mRNA co-regulatory networks in pulmonary large-cell neuroendocrine carcinoma.

Authors:  Cunliang Cai; Qianli Zeng; Guiliang Zhou; Xiangdong Mu
Journal:  Ann Transl Med       Date:  2021-01

4.  Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32.

Authors:  Kang Wu; Jun Zeng; Xulian Shi; Jiajia Xie; Yuqing Li; Haoxiang Zheng; Guoyu Peng; Guanghui Zhu; Dongdong Tang; Song Wu
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.